Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ARQ 621

Drug Profile

ARQ 621

Alternative Names: ARQ-621

Latest Information Update: 04 Apr 2014

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ArQule
  • Class Antineoplastics; Small molecules
  • Mechanism of Action KIF11 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Haematological malignancies; Solid tumours

Most Recent Events

  • 31 Mar 2014 Discontinued - Phase-I for Haematological malignancies (late-stage disease) in USA before March 2014 (Intravenous)
  • 31 Mar 2014 Discontinued - Phase-I for Solid tumours (metastatic disease) in USA before March 2014 (Intravenous)
  • 30 Sep 2011 ArQule completes a phase I trial in Solid tumours (metastatic disease) and Haematological malignancies (late-stage disease) in USA (NCT00825487)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top